| Dr Melvin B Sharf, MD | |
|
974 S Bates St, Birmingham, MI 48009-1976 | |
| (248) 593-9795 | |
| (248) 593-9796 |
| Full Name | Dr Melvin B Sharf |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Location | 974 S Bates St, Birmingham, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912239401 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 31922 (Michigan) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Melvin B Sharf, MD 974 S Bates St, Birmingham, MI 48009-1976 Ph: (248) 593-9795 | Dr Melvin B Sharf, MD 974 S Bates St, Birmingham, MI 48009-1976 Ph: (248) 593-9795 |
News Archive
The Center for Global Development's (CGD) "Global Health Policy" blog on Thursday published two posts addressing family planning funding. In one, Amanda Glassman, director of global health policy and a research fellow at CGD, examines "what organization will actually allocate and spend these additional resources" pledged at the recent London Summit on Family Planning.
India is caught in the midst of a catastrophic smoking epidemic, which is causing one in five of all male deaths in middle age and will cause about one million deaths a year during the 2010s.
Stereotactic radiosurgery (SRS) for cancer patients who receive the treatment for brain metastases decreases the likelihood of local recurrence but shows no positive difference in terms of overall survival (OS) or distant brain metastases (DBMs) rates, when compared to observation alone following surgical resection of brain metastases, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.
Hill-Rom today announced the introduction of Hill-Rom's Advanta(TM) 2 Bed for use in medical-surgical areas of hospitals and care facilities. The new bed brings together ease of use with key safety features and the flexibility to use a variety of care surfaces as needed.
ChemGenex Pharmaceuticals Limited announced today that the U.S. Food & Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for Omapro™ (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
› Verified 4 days ago
Michael Steven Borkin, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 800 S Adams Rd, Ste. 101, Birmingham, MI 48009 Phone: 248-646-9597 Fax: 248-646-4067 | |
Dr. Mitchell S Shek, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 800 S Adams Rd, Suite 101, Birmingham, MI 48009 Phone: 248-646-9597 Fax: 248-646-4067 | |
Dr. Martin M Abbrecht, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 800 S Adams Rd, Suite 101, Birmingham, MI 48009 Phone: 248-646-9597 Fax: 248-646-4067 | |
Dr. Lori A. Haddad, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2151 E 14 Mile Rd, Birmingham, MI 48009 Phone: 248-645-0830 Fax: 248-645-2863 | |
David Vincent Spurlin, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 33301 Woodward Ave, Birmingham, MI 48009 Phone: 248-642-9111 Fax: 248-593-1713 | |
Mrs. Debra Elyse Kaplan, PA Dermatology Medicare: Accepting Medicare Assignments Practice Location: 800 S Adams Rd, Suite 101, Birmingham, MI 48009 Phone: 248-646-9597 Fax: 248-646-4067 |